Sun Pharmaceutical Industries Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended 31 March 2026.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma reported audited standalone total income of ₹2,11,740 million for FY2026, down from ₹2,33,565 million in the prior year, marking approximately 9.7% revenue decline. Standalone profit after tax stood at ₹42,281 million. The auditor issued an unmodified (clean) opinion with no qualifications. The Board recommended a final dividend of ₹5 per share (₹16 total including ₹11 interim already paid). Notable exceptional items included: (a) impairment of SCD-044 drug candidate intangible asset (₹1,515 million) and related R&D costs (₹1,362 million), and (b) ₹2,587 million provision for new Indian labour codes implementation. The company opted for the concessional 22% tax regime under Section 115BAA effective FY2027.
Revenue decline of ~10% year-on-year is a concern, though the exceptional items include non-cash impairment and one-time labour law charges that may not recur. The clean audit opinion and continued dividend payments provide some comfort to shareholders.